27.51 USD
+0.75 (+2.8%)
27.63 USD
+0.12 (+0.44%)
ACAD gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 525 industry peers in the Biotechnology industry. ACAD is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. ACAD has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
- In the past year ACAD was profitable.
- In the past year ACAD had a positive cash flow from operations.
- ACAD had negative earnings in each of the past 5 years.
- ACAD had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
- Looking at the Return On Assets, with a value of 19.63%, ACAD belongs to the top of the industry, outperforming 96.95% of the companies in the same industry.
- ACAD has a Return On Equity of 28.47%. This is amongst the best in the industry. ACAD outperforms 97.52% of its industry peers.
- ACAD has a better Return On Invested Capital (7.66%) than 93.90% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 19.63% | ||
| ROE | 28.47% | ||
| ROIC | 7.66% |
ROA(3y)-13.43%
ROA(5y)-20.05%
ROE(3y)-13.54%
ROE(5y)-23.31%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- Looking at the Profit Margin, with a value of 24.94%, ACAD belongs to the top of the industry, outperforming 95.05% of the companies in the same industry.
- ACAD's Operating Margin of 9.02% is amongst the best of the industry. ACAD outperforms 91.24% of its industry peers.
- ACAD has a Gross Margin of 91.92%. This is amongst the best in the industry. ACAD outperforms 93.33% of its industry peers.
- ACAD's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 9.02% | ||
| PM (TTM) | 24.94% | ||
| GM | 91.92% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.57%
GM growth 5Y2.57%
2. Health
2.1 Basic Checks
- ACAD has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
- The number of shares outstanding for ACAD has been increased compared to 1 year ago.
- The number of shares outstanding for ACAD has been increased compared to 5 years ago.
- There is no outstanding debt for ACAD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
- An Altman-Z score of 6.04 indicates that ACAD is not in any danger for bankruptcy at the moment.
- The Altman-Z score of ACAD (6.04) is better than 75.62% of its industry peers.
- There is no outstanding debt for ACAD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 6.04 |
ROIC/WACC0.86
WACC8.9%
2.3 Liquidity
- ACAD has a Current Ratio of 3.02. This indicates that ACAD is financially healthy and has no problem in meeting its short term obligations.
- The Current ratio of ACAD (3.02) is worse than 63.81% of its industry peers.
- ACAD has a Quick Ratio of 2.94. This indicates that ACAD is financially healthy and has no problem in meeting its short term obligations.
- With a Quick ratio value of 2.94, ACAD is not doing good in the industry: 62.48% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.02 | ||
| Quick Ratio | 2.94 |
3. Growth
3.1 Past
- ACAD shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -14.10%.
- ACAD shows a strong growth in Revenue. In the last year, the Revenue has grown by 121.75%.
EPS 1Y (TTM)-14.1%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%110%
Revenue 1Y (TTM)121.75%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%11.27%
3.2 Future
- ACAD is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 39.40% yearly.
- Based on estimates for the next years, ACAD will show a quite strong growth in Revenue. The Revenue will grow by 10.47% on average per year.
EPS Next Y71.6%
EPS Next 2Y29.52%
EPS Next 3Y35.28%
EPS Next 5Y39.4%
Revenue Next Year11.07%
Revenue Next 2Y11.43%
Revenue Next 3Y11.21%
Revenue Next 5Y10.47%
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
- The Price/Earnings ratio is 41.06, which means the current valuation is very expensive for ACAD.
- Based on the Price/Earnings ratio, ACAD is valued cheaply inside the industry as 91.62% of the companies are valued more expensively.
- When comparing the Price/Earnings ratio of ACAD to the average of the S&P500 Index (27.32), we can say ACAD is valued expensively.
- With a Price/Forward Earnings ratio of 34.16, ACAD can be considered very expensive at the moment.
- 91.81% of the companies in the same industry are more expensive than ACAD, based on the Price/Forward Earnings ratio.
- The average S&P500 Price/Forward Earnings ratio is at 24.30. ACAD is valued slightly more expensive when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 41.06 | ||
| Fwd PE | 34.16 |
4.2 Price Multiples
- Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of ACAD indicates a rather cheap valuation: ACAD is cheaper than 92.95% of the companies listed in the same industry.
- 95.24% of the companies in the same industry are more expensive than ACAD, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 21.38 | ||
| EV/EBITDA | 28.5 |
4.3 Compensation for Growth
- The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
- The decent profitability rating of ACAD may justify a higher PE ratio.
- A more expensive valuation may be justified as ACAD's earnings are expected to grow with 35.28% in the coming years.
PEG (NY)0.57
PEG (5Y)N/A
EPS Next 2Y29.52%
EPS Next 3Y35.28%
5. Dividend
5.1 Amount
- No dividends for ACAD!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
27.51
+0.75 (+2.8%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-05 2025-11-05/amc
Earnings (Next)02-24 2026-02-24/amc
Inst Owners101.21%
Inst Owner Change0.05%
Ins Owners0.26%
Ins Owner Change-3.63%
Market Cap4.65B
Revenue(TTM)1.05B
Net Income(TTM)261.17M
Analysts76.92
Price Target30.87 (12.21%)
Short Float %5.02%
Short Ratio5.82
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)96.34%
Min EPS beat(2)14.46%
Max EPS beat(2)178.22%
EPS beat(4)2
Avg EPS beat(4)20.1%
Min EPS beat(4)-109.07%
Max EPS beat(4)178.22%
EPS beat(8)5
Avg EPS beat(8)29%
EPS beat(12)7
Avg EPS beat(12)26.97%
EPS beat(16)10
Avg EPS beat(16)24.21%
Revenue beat(2)0
Avg Revenue beat(2)-1.06%
Min Revenue beat(2)-1.19%
Max Revenue beat(2)-0.93%
Revenue beat(4)1
Avg Revenue beat(4)-2.59%
Min Revenue beat(4)-8.33%
Max Revenue beat(4)0.08%
Revenue beat(8)3
Avg Revenue beat(8)-1.62%
Revenue beat(12)5
Avg Revenue beat(12)-0.37%
Revenue beat(16)6
Avg Revenue beat(16)-1.45%
PT rev (1m)3.42%
PT rev (3m)4.16%
EPS NQ rev (1m)2.09%
EPS NQ rev (3m)8.32%
EPS NY rev (1m)-1.14%
EPS NY rev (3m)43.73%
Revenue NQ rev (1m)0.07%
Revenue NQ rev (3m)2.41%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.01%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 41.06 | ||
| Fwd PE | 34.16 | ||
| P/S | 4.44 | ||
| P/FCF | 21.38 | ||
| P/OCF | 14.65 | ||
| P/B | 5.07 | ||
| P/tB | 5.78 | ||
| EV/EBITDA | 28.5 |
EPS(TTM)0.67
EY2.44%
EPS(NY)0.81
Fwd EY2.93%
FCF(TTM)1.29
FCFY4.68%
OCF(TTM)1.88
OCFY6.83%
SpS6.19
BVpS5.42
TBVpS4.76
PEG (NY)0.57
PEG (5Y)N/A
Graham Number9.04
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 19.63% | ||
| ROE | 28.47% | ||
| ROCE | 9.69% | ||
| ROIC | 7.66% | ||
| ROICexc | 58.65% | ||
| ROICexgc | 479.54% | ||
| OM | 9.02% | ||
| PM (TTM) | 24.94% | ||
| GM | 91.92% | ||
| FCFM | 20.79% |
ROA(3y)-13.43%
ROA(5y)-20.05%
ROE(3y)-13.54%
ROE(5y)-23.31%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.57%
GM growth 5Y2.57%
F-Score4
Asset Turnover0.79
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 711.57% | ||
| Cap/Sales | 9.55% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 292.92% | ||
| Profit Quality | 83.36% | ||
| Current Ratio | 3.02 | ||
| Quick Ratio | 2.94 | ||
| Altman-Z | 6.04 |
F-Score4
WACC8.9%
ROIC/WACC0.86
Cap/Depr(3y)241.55%
Cap/Depr(5y)203.25%
Cap/Sales(3y)567.7%
Cap/Sales(5y)341.01%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-14.1%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%110%
EPS Next Y71.6%
EPS Next 2Y29.52%
EPS Next 3Y35.28%
EPS Next 5Y39.4%
Revenue 1Y (TTM)121.75%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%11.27%
Revenue Next Year11.07%
Revenue Next 2Y11.43%
Revenue Next 3Y11.21%
Revenue Next 5Y10.47%
EBIT growth 1Y50.49%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year4.82%
EBIT Next 3Y27.27%
EBIT Next 5Y43.9%
FCF growth 1Y264.19%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y443.26%
OCF growth 3YN/A
OCF growth 5YN/A
ACADIA PHARMACEUTICALS INC / ACAD FAQ
What is the fundamental rating for ACAD stock?
ChartMill assigns a fundamental rating of 5 / 10 to ACAD.
What is the valuation status of ACADIA PHARMACEUTICALS INC (ACAD) stock?
ChartMill assigns a valuation rating of 6 / 10 to ACADIA PHARMACEUTICALS INC (ACAD). This can be considered as Fairly Valued.
Can you provide the profitability details for ACADIA PHARMACEUTICALS INC?
ACADIA PHARMACEUTICALS INC (ACAD) has a profitability rating of 6 / 10.
What are the PE and PB ratios of ACADIA PHARMACEUTICALS INC (ACAD) stock?
The Price/Earnings (PE) ratio for ACADIA PHARMACEUTICALS INC (ACAD) is 41.06 and the Price/Book (PB) ratio is 5.07.
Can you provide the financial health for ACAD stock?
The financial health rating of ACADIA PHARMACEUTICALS INC (ACAD) is 7 / 10.